|
The clinical utility of strict laboratory monitoring of CDK 4/6 inhibitors in metastatic breast cancer patients. |
|
|
No Relationships to Disclose |
|
|
Honoraria - Total Health Conferencing |
Consulting or Advisory Role - Pfizer; Puma Biotechnology |
Research Funding - Lilly; Pfizer; Seagen |
Travel, Accommodations, Expenses - Pfizer; Puma Biotechnology; Total Health Conferencing |
|
|
Stock and Other Ownership Interests - Bristol-Myers Squibb (I) |
Consulting or Advisory Role - Arbor Pharmaceuticals |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |
|
|
No Relationships to Disclose |